American Well

AMWL · NYSE

$13.20+$0.87 (+7.06%)TodayMarket closed · Oct 20, 6:34 PM ET

Prev close $12.33

AMWL analyst rating

HoldConsensus of 6 analysts over the last 12 months. 17% rate it a buy.

Strong buy0
Buy1
Hold5
Underperform0
Sell0

12-month price target · 8 analysts

Average $12.58 (−4.7% downside)

Low: $10.10
Now: $13.20
High: $16.80

Upgrades and downgrades

The latest rating actions, newest first

AMWL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Aug 13, 2026	Maintains	Hold	$7.50 → $12.00	37%
Needham	Aug 5, 2026	Maintains	Hold	—	46%
Wells Fargo	Jul 17, 2026	Maintains	Overweight	$9.00 → $16.00	48%
TD Cowen	May 6, 2026	Maintains	Hold	$5.00 → $8.00	62%
Morgan Stanley	May 6, 2026	Maintains	Equal-Weight	$6.00 → $6.50	61%
Stifel	Feb 13, 2026	Maintains	Hold	$6.00 → $5.00	55%
Morgan Stanley	Dec 18, 2025	Maintains	Equal-Weight	$10.50 → $6.00	61%
Wells Fargo	Nov 5, 2025	Maintains	Overweight	$12.00 → $9.00	48%
Stifel	Nov 5, 2025	Maintains	Hold	$8.00 → $6.00	55%

The case for and against

Updated Jul 31, 2026

Bull case

American Well is positioned for long-term success as a leading telehealth company with a strong platform that enables healthcare organizations to provide virtual care across all settings. It has a highly scalable technology and suite of services, and positive financial results have been driven by increasing subscriptions, gross margin expansion, and improved EBITDA loss. The growth outlook is strong, supported by high consumer familiarity with telehealth and potential regulatory tailwinds. While there is still a risk from regulation, AMWL's focus on SaaS-based revenue and strategic restructuring should help mitigate any potential challenges.

Bear case

American Well is facing several potential risks in the healthcare information technology space, including potential slowdowns or cuts in government spending and constrained hospital budgets, which could decrease investments in HCIT. Additionally, increased price competition and delays in purchasing decisions for non-EHR related solutions may also impact the company's growth. Furthermore, American Well's business model is in transition and lack of visibility on larger long-term contracts may hinder its ability to add new logos and upsells, potentially limiting revenue growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.